Day: August 8, 2018

  1. Home
  2. Archives: August 2018

Amylyx Pharmaceuticals Doses First Patient in Phase II Clinical Trial of AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Doses First Patient in Phase II Clinical Trial of AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis  

Recent Posts

  • New ALS Association Partnership with ALS Investment Fund Targets $100 Million in New Funding for ALS Therapeutic Development
  • Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial
  • Apic Bio Announces $40M Series A Financing to Advance Novel Gene Therapies for Rare Genetic Disorders
  • Search for cure against the lethal disease ALS boosted by new investor
  • Orphazyme closes a €14 million Series B Extension

ROBERT BROWN

Scientific Advisory Board